Corbevax, the new vaccine will be available as a precaution dose after the proper completion of waiting period for 6 months or 26 weeks from the time of administration of the second dose of either Covaxin or Covieshield for the vaccination of people above the age of 18 years.
The Center’s most recent action is significant because it marks the first time a booster dose that differs from the one used for initial vaccination against Covid-19 has been permitted in the nation amid escalating Covid-19 instances in numerous states.
The immunisation programme now uses Corbevax, India’s first RBD protein subunit vaccine that was created locally, to immunise children between the ages of 12 and 14.
In its July 20 meeting, the COVID-19 Working Group (CWG) reviewed data from the double-blind randomised phase-3 clinical study that assessed the immunogenicity and safety of a booster dose of the Corbevax vaccine when given to COVID-19-negative adult volunteers between the ages of 18 and 80 who had previously received two doses of either Covishield or Covaxin.
Corbevax will be available as precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for population above 18 years: Union Health Secretary Rajesh Bhushan pic.twitter.com/aMbLDM1cyU
— ANI (@ANI) August 10, 2022